SUNSHINE BIOPHARMA INITIATES COVID-19 TREATMENT MICE STUDY
February 10 2021 - 8:00AM
InvestorsHub NewsWire
SUNSHINE
BIOPHARMA INITIATES COVID-19 TREATMENT MICE
STUDY
Montreal, Quebec, Canada --
February 10, 2021 -- InvestorsHub NewsWire
-- Sunshine Biopharma Inc.
(OTC PINK: "SBFM"), a pharmaceutical company
focused on the research, development and commercialization
of oncology
and antiviral drugs, today
announced that it has initiated a momentous transgenic mice study
of its COVID-19
treatment that has been
under
development since
May of last year. Sunshine Biopharma's COVID-19
treatment consists of a series of small molecules which suppress
replication of the virus
by inhibiting a key
virus encoded protease that is responsible for
compromising
the immune
system of infected patients.
The mice studies
are currently underway at the University of
Georgia, College of Pharmacy.
The mice being used in the study have been genetically
engineered to express the human
angiotensin-converting enzyme 2
(hACE2) transmembrane protein
in their lungs
making them susceptible to lethal infection by
SARS-CoV-2,
the causative agent of COVID-19. The SARS-CoV-2 virus uses the
hACE2 receptor to gain entry into human cells to replicate. The goal of the
study is to determine if Sunshine Biopharma's protease inhibitors
will protect the hACE2-transgenic mice from disease
progression and
death following infection with
SARS-CoV-2 virus.
"Should these
mice
studies prove
successful, we plan to submit the results to
the FDA for authorization to conduct testing on actual COVID-19
patient volunteers in a Phase I clinical trial
setting,"
said Dr. Steve Slilaty, CEO of Sunshine
Biopharma. "We are excited to have
initiated this pivotal study on transgenic mice with the University
of Georgia. The implications of a
COVID-19
treatment
becoming
available are vast. This is
particularly the case in view of the fact
that some of the variants emerging around the world are more
virulent and may escape neutralization by
the current vaccines," he added.
About
Sunshine Biopharma's
Coronavirus Treatment
Severe Acute Respiratory
Syndrome-Coronavirus-2 (SARS-CoV-2) is the etiologic agent of the ongoing COVID-19 pandemic that has claimed the
lives of over 2.3 million people worldwide
since it first
appeared in December 2019. There are currently no drugs
that can effectively arrest replication of the virus in people who
have contracted the illness. On May 22, 2020, Sunshine Biopharma filed a
provisional patent application for several molecules which were
designed by computer-aided modeling to inhibit the Coronavirus
proteases, thus shutting down the ability of the virus to
multiply. Sunshine Biopharma
has since
completed the
synthesis of four such molecules and identified a lead compound,
SBFM-PL4. In collaboration with the University of
Georgia, College of
Pharmacy,
the Company is currently
advancing the
development of SBFM-PL4 through the in vitro testing stage to be followed by mice
studies,
currently underway, before entering clinical trials on COVID-19
patients.
About
Sunshine Biopharma
In addition,
to working on the
development of a treatment for COVID-19, Sunshine Biopharma is engaged in the
development Adva-27a, a unique anticancer compound. Tests
conducted to
date have
demonstrated the effectiveness of Adva-27a at destroying Multidrug
Resistant Cancer Cells, including Pancreatic Cancer
cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and
Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer
indication are planned to be conducted at McGill University's
Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is
owner of all patents and intellectual property pertaining to
Adva-27a.
Safe Harbor
Forward-Looking Statements
This
press release may contain forward looking statements which are
based on current expectations, forecasts, and assumptions that
involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or
expected, including statements related to the amount and timing of
expected revenues statements related to our financial performance,
expected income, distributions, and future growth for upcoming
quarterly and annual periods. These risks and uncertainties are
further defined in filings and reports by the Company with the U.S.
Securities and Exchange Commission (SEC).
Actual
results and the timing of certain events could differ materially
from those projected in or contemplated by the forward-looking
statements due to a number of factors detailed from time to time in
our filings with the SEC. Among other matters, the Company may not
be able to sustain growth or achieve profitability based upon many
factors including but not limited to general stock market
conditions. Reference is hereby made to cautionary statements set
forth in the Company's most recent SEC filings. We have incurred
and will continue to incur significant expenses in our expansion of
our existing as well as new service lines noting there is no
assurance that we will generate enough revenues to offset those
costs in both the near and long term.
Additional
service offerings may expose us to additional legal and regulatory
costs and unknown exposure(s) based upon the various geopolitical
locations we will be providing services in, the impact of which
cannot be predicted at this time.
For
Additional Information Contact:
Camille Sebaaly, CFO
Sunshine Biopharma
Inc.
Direct Line:
514-814-0464
camille.sebaaly@sunshinebiopharma.com
www.sunshinebiopharma.com